VRTX
NEUTRAL
$446.54
Live
Vertex Pharmaceuticals Incorporated · NASDAQ
Target $547.72
(+22.7%)
$362.5
52W Range
$510.77
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 01, 2026
Market cap
$113.44B
P/E
28.9
ROE
22.5%
Profit margin
32.9%
Debt/Equity
0.11
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
VRTX shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Key Strengths
Strong profitability (32.9% margin)
Low debt with D/E ratio of 0.11
Strong ROE of 22.5%
Key Risks
Premium vs Graham Number ($159.83)
Weak financial trend (Piotroski F-Score: 3/9)
AI Fair Value Estimate
Based on comprehensive analysis
$455.77
+2.1% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
43
Moderate
50
60
70
35
0
AI Verdict
VRTX shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Key drivers: Strong profitability (32.9% margin), Low debt with D/E ratio of 0.11, Premium vs Graham Number ($159.83)
Confidence
55%
Value
50/100
Rule-based valuation (P/E + Graham).
Positives
- Insufficient data for clear positives.
Watchpoints
- Trades above Graham Number.
Future
60/100
Rule-based growth outlook.
Positives
- Growth-implied value exceeds price.
Watchpoints
No urgent risks highlighted.
Past
70/100
Historical performance + price trend: Shares moved +109.6% over 5Y and -7.9% over 1Y.
Positives
- ROE sits at 22.5%.
- Healthy profit margin of 32.9%.
Watchpoints
No urgent risks highlighted.
Health
35/100
Balance sheet & liquidity (Z-Score: N/A).
Positives
- Low D/E ratio (0.11).
Watchpoints
No urgent risks highlighted.
Dividend
0/100
Dividend policy fallback.
Positives
- Insufficient data for clear positives.
Watchpoints
- No regular dividend payments.
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$446.54
Analyst Target
$547.72
Upside/Downside
+22.7%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for VRTX and closest competitors.
Updated 2026-03-31
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals Incorporated
Primary
|
+109.6% | +41.7% | -7.9% | +14.0% | -8.1% | -0.5% |
|
BMY
Bristol-Myers Squibb Company
Peer
|
+2.8% | -13.4% | -2.9% | +15.8% | +1.1% | -1.1% |
|
GSK
GSK plc
Peer
|
+77.5% | +69.5% | +48.1% | +25.9% | +0.7% | -5.5% |
|
HCA
HCA Healthcare, Inc.
Peer
|
+225.1% | +111.6% | +37.9% | +22.4% | +12.5% | -0.8% |
|
MCK
McKesson Corporation
Peer
|
+373.0% | +141.7% | +38.6% | +16.5% | +6.3% | -1.2% |
VRT
Vertex Pharmaceuticals Incorporated
Primary
5Y
+109.6%
3Y
+41.7%
1Y
-7.9%
6M
+14.0%
1M
-8.1%
1W
-0.5%
BMY
Bristol-Myers Squibb Company
Peer
5Y
+2.8%
3Y
-13.4%
1Y
-2.9%
6M
+15.8%
1M
+1.1%
1W
-1.1%
GSK
GSK plc
Peer
5Y
+77.5%
3Y
+69.5%
1Y
+48.1%
6M
+25.9%
1M
+0.7%
1W
-5.5%
HCA
HCA Healthcare, Inc.
Peer
5Y
+225.1%
3Y
+111.6%
1Y
+37.9%
6M
+22.4%
1M
+12.5%
1W
-0.8%
MCK
McKesson Corporation
Peer
5Y
+373.0%
3Y
+141.7%
1Y
+38.6%
6M
+16.5%
1M
+6.3%
1W
-1.2%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
28.9
Forward P/E
20.35
PEG Ratio
N/A
P/B Ratio
6.08
P/S Ratio
9.45
EV/Revenue
9.07
EV/EBITDA
22.37
Market Cap
$113.44B
Profitability
Profit margins and return metrics
Profit Margin
32.94%
Operating Margin
39.6%
Gross Margin
53.66%
ROE
22.54%
ROA
12.16%
Growth
Revenue and earnings growth rates
Revenue Growth
+9.5%
Earnings Growth
+32.9%
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
+30.5%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.11
Low debt
Current Ratio
2.9
Strong
Quick Ratio
2.24
Excellent
Cash/Share
$26.01
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$3.2B
Gross Margin
85.4%
Op. Margin
35.4%
Net Margin
37.3%
Total Assets
$25.6B
Liabilities
$7.0B
Equity
$18.7B
Debt/Equity
0.37x
Operating CF
$0.5B
CapEx
$-0.1B
Free Cash Flow
$0.3B
FCF Yield
70%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-04
$N/A
2026-02-12
$4.65
+1.4% surprise
2025-11-03
$4.8
+4.9% surprise
2025-08-04
$3.99
+7.3% surprise
Healthcare Sector Comparison
Comparing VRTX against 560 companies in the Healthcare sector
(34 bullish, 167 neutral, 359 bearish)
P/E Ratio
28.9
This Stock
vs
75.44
Sector Avg
-61.7%
(Discount)
Return on Equity (ROE)
22.54%
This Stock
vs
-88.14%
Sector Avg
-125.6%
(Below Avg)
Profit Margin
32.94%
This Stock
vs
-16.28%
Sector Avg
-302.3%
(Weaker)
Debt to Equity
0.11
This Stock
vs
2.66
Sector Avg
-95.9%
(Less Debt)
Revenue Growth
9.5%
This Stock
vs
124.04%
Sector Avg
-92.3%
(Slower)
Current Ratio
2.9
This Stock
vs
4.47
Sector Avg
-35.2%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals Incorporated
|
NEUTRAL | $113.44B | 28.9 | 22.5% | 32.9% | $446.54 | |
|
BMY
Bristol-Myers Squibb Company
|
NEUTRAL | $111.25B | 18.46 | 33.8% | 12.6% | $54.65 | Compare |
|
GSK
GSK plc
|
BULLISH | $108.22B | 14.42 | 43.3% | 17.5% | $54.22 | Compare |
|
HCA
HCA Healthcare, Inc.
|
BULLISH | $108.0B | 18.28 | -% | 8.5% | $472.65 | Compare |
|
MCK
McKesson Corporation
|
BULLISH | $104.45B | 26.32 | -% | 1.0% | $842.09 | Compare |
VRTX
Vertex...
NEUTRAL
Mkt Cap
$113.4B
P/E
28.9
ROE
22.5%
Price
$446.54
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-13 | BOZIC CARMEN | Officer | Sale | 2,329 | $1,122,089 |
| 2026-03-11 | MCKECHNIE DUNCAN | Officer | Sale | 2,633 | $1,312,340 |
| 2026-03-04 | MCKECHNIE DUNCAN | Officer | Sale | 2,437 | $1,158,306 |
| 2026-03-02 | LIU JOY | Officer | Sale | 892 | $442,396 |
| 2026-02-27 | BOZIC CARMEN | Officer | Sale | 2,329 | $1,118,642 |
| 2026-02-27 | KEWALRAMANI RESHMA | Chief Executive Officer | Sale | 40,000 | $19,738,855 |
| 2026-02-26 | AMBROSE KRISTEN | Officer | Sale | 357 | $172,560 |
| 2026-02-25 | AMBROSE KRISTEN | Officer | Sale | 223 | $108,456 |
| 2026-02-25 | ATKINSON EDWARD MORROW III | Chief Technology Officer | Sale | 668 | $324,882 |
| 2026-02-25 | MCKECHNIE DUNCAN | Officer | Sale | 4,910 | $2,394,365 |
| 2026-02-25 | BUNNAGE MARK E. | Officer | Sale | 620 | $301,537 |
| 2026-02-25 | TATSIS OURANIA | Officer | Sale | 260 | $126,451 |
| 2026-02-25 | BILLER JONATHAN PRIM | Officer | Sale | 945 | $459,601 |
| 2026-02-25 | SACHDEV AMIT | Officer | Sale | 1,846 | $897,802 |
| 2026-02-19 | SACHDEV AMIT | Officer | Sale | 58,613 | $27,479,583 |
BOZIC CARMEN
Officer
2026-03-13
2,329 shares
·
$1,122,089
MCKECHNIE DUNCAN
Officer
2026-03-11
2,633 shares
·
$1,312,340
MCKECHNIE DUNCAN
Officer
2026-03-04
2,437 shares
·
$1,158,306
LIU JOY
Officer
2026-03-02
892 shares
·
$442,396
BOZIC CARMEN
Officer
2026-02-27
2,329 shares
·
$1,118,642
KEWALRAMANI RESHMA
Chief Executive Officer
2026-02-27
40,000 shares
·
$19,738,855
AMBROSE KRISTEN
Officer
2026-02-26
357 shares
·
$172,560
AMBROSE KRISTEN
Officer
2026-02-25
223 shares
·
$108,456
ATKINSON EDWARD MORROW III
Chief Technology Officer
2026-02-25
668 shares
·
$324,882
MCKECHNIE DUNCAN
Officer
2026-02-25
4,910 shares
·
$2,394,365
BUNNAGE MARK E.
Officer
2026-02-25
620 shares
·
$301,537
TATSIS OURANIA
Officer
2026-02-25
260 shares
·
$126,451
BILLER JONATHAN PRIM
Officer
2026-02-25
945 shares
·
$459,601
SACHDEV AMIT
Officer
2026-02-25
1,846 shares
·
$897,802
SACHDEV AMIT
Officer
2026-02-19
58,613 shares
·
$27,479,583
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
29 analysts
Maxim Group
2026-03-18
Hold
Buy
Truist Securities
2026-03-11
Buy
Buy
Morgan Stanley
2026-03-10
Overweight
Overweight
B of A Securities
2026-03-10
Buy
Buy
Citigroup
2026-03-10
Buy
Buy
Oppenheimer
2026-03-10
Outperform
Outperform
Jefferies
2026-03-10
Buy
HC Wainwright & Co.
2026-03-10
Buy
Buy
Canaccord Genuity
2026-02-17
Hold
Hold
Barclays
2026-02-17
Overweight
Overweight
Past News Coverage
Recent headlines mentioning VRTX from our newsroom.
Newest → oldest
No matching news yet.